An interventional study of Video recording and Notes Instruction in Amyotrophic Lateral Sclerosis (ALS), sponsored by Trustees of Dartmouth College. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Trustees of Dartmouth College · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 5th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 82 with no phase, reaches primary completion later than 97 of the 128 other live ones, and was the 420th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 33 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Trustees of Dartmouth College is the lead sponsor of 38 studies on the registry; 17 are open to participants now.
Trustees of Dartmouth College has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC). In these multidisciplinary clinics, which occur every 3 to 4 months, people with ALS see up to 12 different healthcare providers (e.g., speech therapy, physical therapy, the ALS doctor). These clinics can last from three to five hours, and across these three to five hours people with ALS and their caregivers receive a lot of information that is critical to the care and quality of life for people with ALS. However, this information can be difficult to remember given the large amount of information that is conveyed. The current standard for providing take-home information about the visit is to provide patients with a written after-visit summary and access to their doctor's notes about the visit, typically through the patient portal. This study tests whether providing participants with video recordings of their MDC visits improves their quality of life and the quality of life of their caregivers. The study will enroll 400 pairs of people with ALS and their caregivers from eight different sites in the United States. Half of the participants in the study will receive their after-visit summary notes (the NOTES condition) and the other half of the participants will receive both their summary notes, but will also receive video recordings of their MDC visits that they can watch on their own at home (the VIDEO condition). The study will last for 12 months, with participants receiving NOTES or VIDEO at each of their regularly-scheduled MDCs during the 12 months. The study will test whether caregiver and patient participants in the VIDEO condition experience better quality of life than those in the NOTES condition at 1 month, 6 months, and 12 months from study enrollment. The results of this study will help determine what is the most effective approach to communicating MDC information to people with ALS and their caregivers.
BACKGROUND AND SIGNIFICANCE
Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. People with ALS (pwALS) and their caregivers, attend 3 - 5 hour long multidisciplinary clinics (MDC) every 3 months where they meet with up to 12 specialists. The goal of treatment is to maintain pwALS quality of life (QOL). Optimal information from MDCs is necessary for the intensive at-home management which gets more complex as ALS progresses. Yet 40% of recommendations are forgotten by pwALS negatively impacting QOL, while caregivers report information deficits increasing caregiving burden. Patient portal access to MDC notes is standard, and can improve recall and health outcomes, yet concerns exist about their layout, comprehensiveness and challenges for people with low health literacy. An underutilized strategy to share MDC information is video recording. Systematic reviews find recordings improve health outcomes, and the use of video in an ALS context may be particularly helpful given complicated at-home management. The study will determine what is the most effective approach to communicating MDC information to facilitate optimal delivery of care for pwALS and their caregivers
STUDY AIMS
Aim 1. Assess the comparative effectiveness of written MDC visit information provided to pwALS and their caregivers via the patient portal (NOTES) versus NOTES plus visit video recording (VIDEO) on patient and caregiver quality of life.
Aim 2. Determine whether patient and caregiver health literacy and rapid ALS disease progression are modifying factors on the comparative effectiveness of NOTES versus VIDEO on primary outcomes.
Aim 3. Identify system and patient-level factors that impact the implementation and use of multimodal strategies of MDC information exchange by a diverse sample of pwALS, caregivers, clinicians and health system leaders.
Hypothesis (Main Effect): Compared to those receiving NOTES, pwALS randomized to also receive routine VIDEO recordings of their MDC visit will report better QOL via improved care-management (i.e., treatment adherence), self-management ability, satisfaction with communication and reduced healthcare utilization at 12 months; there will be larger relative benefits for pwALS, and caregivers, with low health literacy and rapid disease progression. The investigators also hypothesize that compared to NOTES alone, caregivers in the VIDEO arm will report better QOL, improved preparedness and less burden at 12 months.
STUDY DESCRIPTION
Overall study design
This study is a multisite, two-arm, parallel group, patient-randomized, controlled, comparative effectiveness trial with 12-month follow-up. Adopting a Hybrid Type 1 design, the investigators will also examine implementation barriers and facilitators using interviews guided by the Consolidated Framework for Implementation Research Framework 2.0.
Comparators
Comparator 1 (NOTES): After the initial MDC study staff will provide a 15-minute training to orient participants to the portal and how to access visit notes.
Comparator 2 (VIDEO): All MDC visits will be video-recorded over 12 months, using HealthPAL, an NIH-funded HIPAA-compliant personal health library developed by PI Barr. Participants in the VIDEO arm will receive orientation to the patient portal and HealthPAL.
Following each scheduled MDC, pwALS and caregivers in both groups will receive emails reminding them to watch the visit video recording and/or review their note: 1) within 48 hours of the visit to remind them of the visit discussion and self-management tasks they may have; and 2) 3 days before their next MDC visit to prepare for their next MDC visit.
Study Population
The study recruit 400 patient and caregiver pairs (400 pwALS and their 400 caregivers) from eight MDC sites (∼50 pairs per site): Dartmouth Health (Lebanon, NH), Massachusetts General Hospital (Boston, MA), Mayo Clinics (Scottsdale, AZ, and Jacksonville, FL), Penn State Health (Hershey, PA), University of Pittsburgh Medical Center (Pittsburgh, PA), University of Wisconsin (Madison, WI) and Virginia Commonwealth University (Richmond, VA). The study will include pwALS, age ≥18 years, who plan to attend MDC visits for 12-months, speak English or Spanish, have ≥12 months projected survival, and internet access and their primary caregivers (family member or friend), ≥18 years who attends MDC visits or assist with their care.
Outcomes
Primary outcomes: For people with ALS, the total score on the ALSAQ-40 (a self report survey measure of quality of life for people with ALS) is the primary outcome. For caregivers, the total score on the PROMIS-10 (a self report survey measure of quality of life); Secondary outcomes include exercise adherence, medication adherence, adherence to MDC recommendations, self-management ability, patient satisfaction with communication, caregiver visit engagement, preparedness for caregiving, and caregiver burden. Exploratory outcomes include healthcare utilization.
Timeframe
Twelve-month follow-up for all outcomes.
Inclusion Criteria for People with ALS:
Exclusion Criteria for People with ALS:
Inclusion Criteria for Caregivers:
Exclusion Criteria for Caregivers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm of the study will have their multidisciplinary clinic visits video recorded and they will be able to access those video recordings on their own at home. They will also be able to access their doctor's notes and after visit summaries through their patient portal.
Behavioral: Video recording · Behavioral: Notes Instruction
Participants in this arm of the study will have their standard access to their doctor's notes and after visit summaries through their patient portal. They will also be provided with training on how to access and share access to their patient portal notes.
Behavioral: Notes Instruction
We will video record participants' multidisciplinary clinic (MDC) visits for 12 months. Participants will access the videos in HealthPAL, an NIH-funded, HIPAA-compliant personal health library developed with older adults and caregivers, available in Spanish and English. Each specialist visited with during the MDC will have a 'chapter' in HealthPAL that can be reviewed online at home by participants. Participants will receive orientation and training on both their patient portal and HealthPAL, including how to review and share their recordings using a take-home manual (an instructions video is also available in HealthPAL).
Participants will be given instruction on how to view their after-visit summaries and doctors' notes in their patient portal, as well as how to give other trusted family members or friends access to their visit notes.
For Caregiver Participants: the total score on the PROMIS-10 self report survey
The Patient-Reported Outcomes Measurement Information System-10 (PROMIS-10) is a self-report measure of quality of life. The PROMIS-10 will be administered to caregivers via a secure online survey. We will analyze the total score on the PROMIS-10 as the primary outcome for caregiver participants.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
For Patient Participants: The total score on the ALSAQ-40 self report survey.
The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) is a self-report measure of quality of life for people with ALS. The ALSAQ-40 will be administered via a secure online survey.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Patient Activation Measure Short Form (PAM-SF)
The PAM-SF is a self-reported measure of self-management ability. It will be administered to participants with ALS via a secure online survey.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Exercise Adherence Rating Scale (EARS)
The EARS is a self-report measure of exercise adherence. It will be administered to participants with ALS via a secure online survey.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Adherence to Refills and Medications Scale (ARMS)
The ARMS is a self-report measure of medication adherence. It will be administered to participants with ALS via a secure online survey.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Adherence to Multidisciplinary Clinic Recommendations
Using a secure online survey, participants with ALS will indicate which of a list of possible clinic recommendations they received and the extent to which they adhered to those recommendations.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Interpersonal Processes of Care (IPC) Survey
The IPC is a self-report measure of satisfaction with the communication during a doctor visit. It will be administered via a secure online survey to participants with ALS.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Caregiver Perceptions About Communication with Clinical Team (CAPACITY) Survey
CAPACITY is a self-report measure of satisfaction with the communication during a doctor visit. It will be administered via a secure online survey to caregivers attending multidisciplinary clinic visits with the patient participants.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Preparedness for Caregiving Scale
The Preparedness for Caregiving Scale is a self-report measure, completed by the caregiver, of the caregiver's self-perceived readiness to provide care across different domains (e.g., physical, emotional). It will be administered to caregivers via a secure online survey.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total Score on the Burden Scale for Family Caregivers - Short Form (BSFC)
The BSFC is a self-report measure of caregiver burden. It will be administered via a secure online survey to participant caregivers.
Time frame: Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
Total number of patient phone calls and patient portal messages to the clinical care team.
Collected using the participant with ALS's electronic medical record.
Time frame: From enrollment to 12 months after enrollment.
Total number of emergency room visits and hospitalizations.
Collected from the participant with ALS's electronic medical record.
Time frame: From enrollment to 12 months after enrollment.
Plan to share: Yes — Deidentified non-video data that will be shared include demographic data (e.g., age, gender, language, race, ethnicity, income); information on use of the patient portal and video recordings; researcher field notes (e.g., if a caregiver is present at a visit, whether the visit was telehealth or in-person); participant-reported survey responses (e.g., assessments measuring cognitive function, health literacy, quality of life, adherence, self-management ability, caregiver burden, caregiver preparedness). We will also share raw video recordings of the participants' multidisciplinary clinic visits. Raw video recordings will not be accompanied by personal identifying information, but they will not be stripped of any visual or auditory features that could potentially identify an individual.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: We anticipate IPD data being available for sharing within 1 year of the study close (September 2031) in perpetuity.
Access criteria: Data will be stored in a secured data archive. Access to the data will be restricted and available only upon request from researchers with a clear research plan for the data, whom have IRB approval, and the training and resources to carry out the research plan.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 36 months after the start.
Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 36 months is close to that.
Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Trustees of Dartmouth College